Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan for Sleep Disturbance in Reflux Esophagitis
NCT03116841Phase 4Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vonoprazan in reflux esophagitis, sponsored by Takeda. Primary endpoint: Pittsburgh Sleep Quality Index Global Score at Week 8. Started Aug 2017; status: completed.
02
Drugs
vonoprazan
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT03116841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116841.